GemVax&KAEL Statistics

Total Valuation

GemVax&KAEL has a market cap or net worth of KRW 1.10 trillion. The enterprise value is 1.14 trillion.

Market Cap	1.10T
Enterprise Value	1.14T

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

GemVax&KAEL has 43.95 million shares outstanding. The number of shares has increased by 4.08% in one year.

Current Share Class	43.95M
Shares Outstanding	43.95M
Shares Change (YoY)	+4.08%
Shares Change (QoQ)	+0.73%
Owned by Insiders (%)	1.13%
Owned by Institutions (%)	4.34%
Float	32.49M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	13.48
PB Ratio	19.20
P/TBV Ratio	20.40
P/FCF Ratio	9,873.08
P/OCF Ratio	991.33
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-100.29
EV / Sales	13.95
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	10,215.53

Financial Position

The company has a current ratio of 0.66, with a Debt / Equity ratio of 1.06.

Current Ratio	0.66
Quick Ratio	0.45
Debt / Equity	1.06
Debt / EBITDA	7.52
Debt / FCF	547.11
Interest Coverage	0.57

Financial Efficiency

Return on equity (ROE) is -26.29% and return on invested capital (ROIC) is 2.14%.

Return on Equity (ROE)	-26.29%
Return on Assets (ROA)	1.53%
Return on Invested Capital (ROIC)	2.14%
Return on Capital Employed (ROCE)	4.06%
Weighted Average Cost of Capital (WACC)	12.07%
Revenue Per Employee	447.97M
Profits Per Employee	-62.29M
Employee Count	182
Asset Turnover	0.53
Inventory Turnover	6.51

Taxes

Income Tax	-90.48M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -30.94% in the last 52 weeks. The beta is 1.46, so GemVax&KAEL's price volatility has been higher than the market average.

Beta (5Y)	1.46
52-Week Price Change	-30.94%
50-Day Moving Average	34,845.00
200-Day Moving Average	41,238.75
Relative Strength Index (RSI)	36.61
Average Volume (20 Days)	372,055

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, GemVax&KAEL had revenue of KRW 81.53 billion and -11.34 billion in losses. Loss per share was -275.00.

Revenue	81.53B
Gross Profit	34.82B
Operating Income	3.79B
Pretax Income	-11.43B
Net Income	-11.34B
EBITDA	8.10B
EBIT	3.79B
Loss Per Share	-275.00

Full Income Statement

Balance Sheet

The company has 22.78 billion in cash and 60.89 billion in debt, giving a net cash position of -38.12 billion or -867.15 per share.

Cash & Cash Equivalents	22.78B
Total Debt	60.89B
Net Cash	-38.12B
Net Cash Per Share	-867.15
Equity (Book Value)	57.23B
Book Value Per Share	1,357.80
Working Capital	-22.52B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.11 billion and capital expenditures -997.19 million, giving a free cash flow of 111.30 million.

Operating Cash Flow	1.11B
Capital Expenditures	-997.19M
Depreciation & Amortization	4.31B
Net Borrowing	15.73B
Free Cash Flow	111.30M
FCF Per Share	2.53

Full Cash Flow Statement

Margins

Gross margin is 42.70%, with operating and profit margins of 4.65% and -13.90%.

Gross Margin	42.70%
Operating Margin	4.65%
Pretax Margin	-14.02%
Profit Margin	-13.90%
EBITDA Margin	9.94%
EBIT Margin	4.65%
FCF Margin	0.14%

Dividends & Yields

GemVax&KAEL does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.08%
Shareholder Yield	-4.08%
Earnings Yield	-1.03%
FCF Yield	0.01%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

GemVax&KAEL has an Altman Z-Score of 9.86 and a Piotroski F-Score of 7.

Altman Z-Score	9.86
Piotroski F-Score	7